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SurgicalSolutions
Colon Cancer Vaccine:
Clinical Trial Enrollment Continues
Surgeon Speaks
“Patients truly benefit from the close
collaboration between surgeons and
clinician-researchers at Jefferson.
Dr. Waldman and I have been working
together for nearly 20 years – and we’re
collaborating even more closely as we
continue identifying potential patients
for the vaccine study.
“Patients with Stage 1 or 2 colon cancer
have a high survivability rate – usually
from 75 to 95 percent. However,
between 5 and 25 percent will succumb
to their disease.

Colorectal surgeon Scott Goldstein, MD (center) in the laboratory with long-time collaborator Scott Waldman, MD, PhD (left), and
immunologist Adam Snook, PhD (right). The team is conducting a promising Phase I vaccine trial for colon cancer at Jefferson.

Clinician-researchers at Jefferson are
testing a vaccine that may support
better outcomes for patients with
colon cancer.
For people with Stage 1, 2 or 3 colon
cancer, surgery is the standard of care.
For most, it turns out to be a cure. But
for a minority of patients who undergo
surgery for colon cancer, disease later
emerges in the liver, lung or another
part of the body. When that occurs,
the prognosis is poor.
“Once you have metastatic disease
in colon cancer, a clock is ticking,”
explains Scott Waldman, MD,
PhD, Associate Dean, Clinical and
Translational Research and Samuel
M.V. Hamilton Professor and Chair,
Department of Pharmacology and
Experimental Therapeutics. “With this
vaccine, which is administered after
surgery, we’re trying to get ahead of
that. The idea is to boost the patient’s
own immune system to attack
microscopic nests of cells before
they become a real threat.”
Dr. Waldman notes that this Phase I
vaccine trial represents the culmination
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of 18 years of work at Jefferson –
and is a powerful example of the
institution’s capabilities in discovery as
well as translating research into clinical
practice through close collaboration
with Jefferson surgeons.

“...a single shot
could protect
patients against
the cancer cells
that remain in their
system after surgery”
It was in 1996 that Jefferson
researchers first identified a protein
expressed by colon cancer that acts
as an identification tag, also known
as a marker. Much like flu vaccines
train the immune system to fight
cells infected with flu virus, this
experimental cancer vaccine is
intended to teach the immune system
to recognize and destroy cancer
cells expressing this marker when

they begin to grow in new locations
throughout the body.
The final test – whether or not the
cancer returns – won’t be known for
a number of years and will require
additional clinical trials.
“If the vaccine works as we expect,
a single shot could protect patients
against the cancer cells that remain
in their system after surgery while
also offering lifelong protection from
a recurrence,” Dr. Waldman says. He
adds that the same approach could
also apply to patients with some
forms of esophageal, gastric and
pancreatic cancers. (A similar Phase
II immunotherapy trial for pancreatic
cancer is currently accruing patients
at Jefferson.)
To be eligible for the current clinical
trial, patients must have Stage 1 or
2 colon cancer. They must have
undergone surgery (at any hospital)
to remove the primary tumor but
must not have had chemotherapy or
radiotherapy. They must receive the
vaccine at least two months but not
more than three years after surgery.

“In patients with early-stage colon
cancer, the risks of adjuvant
chemotherapy – that is, additional
treatment given after surgery to lower
the risk of the cancer returning –
outweigh the benefits. We closely follow
these patients following surgery. If we
see evidence of metastatic disease, we
proceed with surgery or chemotherapy.
“Our goal is to avoid that waiting
game – and protect these patients
with a safe, non-toxic therapy.
So far, the vaccine has been shown
to be extremely safe, which is very
encouraging.”
Scott D. Goldstein, MD, FACS
Director, Division of Colon & Rectal Surgery
Professor of Surgery
For more information and to learn
if you may be eligible to enroll in
the trial, call 877-503-9352.

Since the trial’s initiation in
November 2013, five patients
have received the vaccine, and Dr.
Waldman reports that no one has
had any adverse effects. Additional
patients are in various stages of
enrollment, but more patients are
still needed for this ongoing trial.
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